USANA Health Sciences (NYSE:USNA) Hits New 12-Month Low – Should You Sell?

USANA Health Sciences, Inc. (NYSE:USNA)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $27.58 and last traded at $28.03, with a volume of 59771 shares trading hands. The stock had previously closed at $27.98.

Analysts Set New Price Targets

USNA has been the subject of several recent analyst reports. DA Davidson cut their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Finally, Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

USANA Health Sciences Stock Performance

The company has a market cap of $532.84 million, a price-to-earnings ratio of 9.94, a P/E/G ratio of 0.93 and a beta of 0.98. The company has a fifty day moving average of $32.39 and a two-hundred day moving average of $35.78.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The business had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Equities analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,234 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now directly owns 12,775 shares in the company, valued at $421,319.50. This represents a 20.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Joshua Foukas sold 5,732 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock worth $500,285 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Martingale Asset Management L P lifted its stake in shares of USANA Health Sciences by 2.1% during the 3rd quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock valued at $634,000 after buying an additional 340 shares in the last quarter. KBC Group NV increased its holdings in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after acquiring an additional 519 shares during the last quarter. R Squared Ltd bought a new stake in shares of USANA Health Sciences in the 4th quarter worth about $28,000. Safe Harbor Fiduciary LLC bought a new position in USANA Health Sciences during the 3rd quarter valued at about $30,000. Finally, Exchange Traded Concepts LLC lifted its position in shares of USANA Health Sciences by 11.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company’s stock worth $308,000 after purchasing an additional 869 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.